James P. Jewell - Concepedia

Concepedia

Author

James P. Jewell

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

J. Jewell, J. P. Jewell, James Jewell, James P. Jewell

39

Publications

1.8K

Citations

15

H-Index

51

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy

JP

About

James P. Jewell is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	1.2K
2	Biochemistry	9	9	430
3	Natural Sciences	5	5	237
4	Engineering	2	2	61
5	Cell Biology	2	2	109

James P. Jewell

×

17

Publications

1.8K

Citations

15

H-Index

	Year	Citations
An orally available non-nucleotide STING agonist with antitumor activity Bo‐Sheng Pan, Samanthi A. Perera, Jennifer Piesvaux, Science Antitumor ActivityImmunologyImmunoeditingImmunologic MechanismPharmacotherapy	2020	609
[<sup>18</sup>F]MK-9470, a positron emission tomography (PET) tracer for<i>in vivo</i>human PET brain imaging of the cannabinoid-1 receptor H. Donald Burns, Koen Van Laere, Sandra Sanabria Bohórquez, Proceedings of the National Academy of Sciences	2007	311
Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING Tony Siu, Michael D. Altman, Gretchen A. Baltus, ACS Medicinal Chemistry Letters	2018	163
Discovery of <i>N</i>-[(1<i>S</i>,2<i>S</i>)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity Linus S. Lin, Thomas J. Lanza, James P. Jewell, Journal of Medicinal Chemistry Cannabis UseMolecular PharmacologyMedicinal ChemistryCompound 48Biochemistry	2006	122
Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1 S,2 S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents Tung M. Fong, Xiao-Ming Guan, Donald J. Marsh, Journal of Pharmacology and Experimental Therapeutics	2007	100
MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor Bo‐Sheng Pan, Grace K.Y. Chan, Mélissa Chénard, Cancer Research Activated C-met ReceptorCell CultureCancer BiologyTumor BiologyMolecular Pharmacology	2010	82
Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques Koppara Samuel, Wenji Yin, Ralph A. Stearns, Journal of Mass Spectrometry Hit IdentificationMetabolic ActivationMetabolomic ProfilingLead IdentificationNew Drug	2003	77
Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity Iyassu K. Sebhat, Christopher S. Franklin, Michael M.‐C. Lo, ACS Medicinal Chemistry Letters ObesityCompound 22BiochemistryFunctional SelectivityMedicine	2010	65
Discovery of a 5<i>H</i>-Benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer Jason D. Katz, James P. Jewell, David Guérin, Journal of Medicinal Chemistry Tumor BiologyAberrant C-met SignalingDrug TargetC-met KinaseBiochemistry	2011	60
Discovery of<i>N</i>-{(1<i>S</i>,2<i>S</i>)-2-(3-Cyanophenyl)- 3-[4-(2-[<sup>18</sup>F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a Cannabinoid-1 Receptor Positron Emission Tomography Tracer Suitable for Clinical Use Ping Liu, Linus S. Lin, Terence G. Hamill, Journal of Medicinal Chemistry Drug TargetEngineeringCannabinoid PharmacologyClinical UsePositron Emission Tomography	2007	36

Page 1